PODO/SVTERT1522024-05-16T08:32:36+00:00

Kidney

PODO/SVTERT152

Evercyte’s human urine-derived podocyte cell line PODO/SVTERT152 can be grown without limitations while maintaining expression of cell type specific markers and function. Therefore, these cells are valuable as standardized in vitro model to study kidney diseases such as glomerulopathies. Moreover, the cells are useful for toxicity studies in pre-clinical drug development as well as for the development of glomerulus-protective therapeutics.

from

€ 1600,–

PODO/SVTERT152
Cat#: CLHT-033-0152

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

Related Products

PodoUp3 cell culture medium for growth of PODO/SVTERT152 cells

Related Services

establishment of podocyte cell lines from urine of kidney disease patients

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

about our cells

telomerized (hTERT immortalized) cells in biotechnology and biomedicine

kidney tissue-derived podocytes

PODO/TERT256 cells from healthy donor

Related Products

cell culture medium for growth of human telomerized podocytes

Related Services

testing cytotoxic effects of drugs on human relevant and standardizable cells

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

from

€ 1300,–

PODO/SVTERT152
Cat#: CLHT-033-0152

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

Go to Top